Control of Metastatic Tumor Growth in a Patient with Sporadic Metastatic Malignant Peripheral Nerve Sheath Tumor (sMPNST) Using the Hope Protocol, an Alternative Treatment Regimen for Cancer

Erlinda Gordon,Frederick L Hall,Don A Brigham,Jonathan Dang,Sant P Chawla,Lance Ostendorf,Omid Jafari,Nicole L Angel

doi:10.15342/ijms.2021.453

Abstract

Metastatic sporadic malignant peripheral nerve sheath tumor (sMPNST) is associated with only 17% five-year survival rate using standard chemotherapy and there are no 10-year survival reports with the exception of a case report wherein a patient with metastatic sMPNST is still alive with no active disease and on no further cancer therapy, >12 years from DeltaRex-G treatment initiation. In this case report, we describe an interim alternative treatment regimen designed and used by a patient with metastatic sMPNST, while awaiting the return, GMP bioproduction, and QC certification of DeltaRex-G as a potential treatment option. We report on the successful control of metastatic tumor growth over a one-year treatment period using the Hope Protocol consisting of artemisinin, curcumin, cannabis oil, disulfiram, fenbendazole, mebendazole, albendazole, atorvastatin, doxycycline, vitamin C, vitamin E, a plant-based diet, sans refined sugar, yoga, acupuncture, meditation, exercise and hot sauna, and we discuss their biochemical mechanisms of action.

Highlights

Malignant peripheral nerve sheath tumors (MPNSTs) are a rare, aggressive, and deadly subtype of soft tissue sarcomas (STS) wherein disease management upon surgical resection remains a challenge with poor prognosis due to a diversity of metastatic karyotypes, a multiplicity of signaling pathways, a dismal drug response rate, and a lack of durable clinical responses
Ten-year survival rates have not been reported for metastatic sporadic malignant peripheral nerve sheath tumor (sMPNST) with the exception of a case report wherein a patient with metastatic sMPNST is still alive with no active disease and on no further cancer therapy, >12 years from DeltaRex-G treatment initiation.[2]
The mechanisms of action of individual treatments and repurposed drugs used by this MPNST patient have been extensively studied, providing individual rationale for their use

Summary

Introduction

Malignant peripheral nerve sheath tumors (MPNSTs) are a rare, aggressive, and deadly subtype of soft tissue sarcomas (STS) wherein disease management upon surgical resection remains a challenge with poor prognosis due to a diversity of metastatic karyotypes, a multiplicity of signaling pathways, a dismal drug response rate, and a lack of durable clinical responses.

Results

Conclusion